Evolus Analyst Ratings
H.C. Wainwright Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $27
Evolus Analyst Ratings
H.C. Wainwright Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $27
Evolus Is Maintained at Overweight by Barclays
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Evolus Price Target Maintained With a $22.00/Share by Needham
Evolus Buy Rating Justified by Strong Market Positioning and Growth Projections
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Raises Target Price to $20
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $23
Evolus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Evolus (EOLS) and Humana (HUM)
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $16 to $27
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $22 to $27
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Evolus (EOLS) Receives a Buy From Stifel Nicolaus
Evolus Rides High on Jeuveau Sales Surge and Financial Milestones: A Bullish Buy Rating
Evolus Analyst Ratings
Evolus Outperforms With Strong Q2 Revenue and Raised Guidance: A Positive Outlook Reaffirms $23 Price Target
No Data
No Data